Sector News

J&J buying Vogue Int’l for about $3.3B

June 3, 2016
Life sciences

Johnson & Johnson is buying hair care products maker Vogue International for about $3.3 billion.

Privately-held Vogue also sells other personal care products.

The acquisition will give Johnson & Johnson the OGX collection of shampoos, conditioners, treatments, styling products, body care and bath products, the FX hair styling product line and the Proganix and Maui Moisture hair care lines.

Vogue’s hair care products are sold in the U.S. and 38 other countries.

Johnson & Johnson, based in New Brunswick, N.J., has brands including Neutrogena and Band-Aid.

The deal is expected to close in the third quarter.

Johnson & Johnson said that the transaction isn’t expected to impact its previously announced full-year sales and earnings forecasts.

J&J shares rose 47 cents to $113.25 in morning trading Thursday. Its shares are up more than 13 percent over the past year.

Source: Associated Press via Salt Lake Tribune

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”